Empagliflozin is associated with improved beta cell function in subjects with impaired fasting glucose, according to a study published online June 13 in Diabetes.
Newsroom
Empagliflozin is associated with improved beta cell function in subjects with impaired fasting glucose, according to a study published online June 13 in Diabetes.